|
19 Mar 2019 |
Alkahest Doses First Subject in Phase 2 Clinical Trial of Lead Candidate in Patients with Severe Alzheimer's Disease
|
|
19 Mar 2019 |
Cytovation Initiates Clinical Development Programme With CyPep-1, a First-in-class Lytic Agent for Tumor Immunotherapy
|
|
19 Mar 2019 |
BioAegis Therapeutics Completes Enrollment in its Phase 1b/2a Dose-Ranging Safety Study of Recombinant Plasma Gelsolin for Community-Acquired Pneumonia
|
|
15 Mar 2019 |
Xeris Pharmaceuticals Doses First Patient in Phase 2 Trial Evaluating Its Ready-to-Use Glucagon to Address Exercise-Induced Hypoglycemia
|
|
15 Mar 2019 |
ImmunogenX Initiates Phase 2 Trial for its Lead Therapeutic and Diagnostic Candidates Latiglutenase and CypCel
|
|
15 Mar 2019 |
Spectrum Pharmaceuticals Provides BLA Filing Update for ROLONTIS® (eflapegrastim)
|
|
08 Mar 2019 |
FDA Accepts Supplemental Biologics License Applications (sBLAs) for BOTOX® (onabotulinumtoxinA) for Pediatric Patients with Upper and Lower Limb Spasticity
|
|
07 Mar 2019 |
Baxter Announces U.S. FDA Approval and Launch of Ready-to-Use Cardiovascular Medicine Eptifibatide
|
|
06 Mar 2019 |
Zealand Pharma doses first patient in Phase 3 trial with dasiglucagon for the treatment of congenital hyperinsulinism
|
|
05 Mar 2019 |
I-Mab Biopharma Announces the Achievement of First Patient Dosing in Phase 1b/2a China Trial of TJ107 for Cancer and Chemotherapy-induced Lymphopenia
|
|
05 Mar 2019 |
Lilly to Introduce Lower-Priced Insulin
|
|
05 Mar 2019 |
Ascendis Pharma Announces Once-weekly TransCon™ Growth Hormone Demonstrated Superiority on Primary Endpoint Compared to a Daily Growth Hormone in Phase 3 heiGHt Trial for Pediatric Growth Hormone Deficiency
|
|
04 Mar 2019 |
Ozempic® superior in lowering blood sugar and weight vs placebo, both in combination with SGLT-2 inhibitors
|
|
02 Mar 2019 |
Hansa Biopharma Announces European Medicines Agency Accepts Marketing Authorization Application for IDEFIRIX™ (imlifidase)
|
|
02 Mar 2019 |
Novo Nordisk files for a label update for Fiasp® to the EMA and the FDA seeking approval for use in children and adolescents
|
|
02 Mar 2019 |
BioMarin Receives Positive CHMP Opinion in Europe for Palynziq® (pegvaliase Injection) for Treatment of Patients with Phenylketonuria (PKU) Aged 16 and Older
|
|
27 Feb 2019 |
Alkermes Initiates Clinical Study of ALKS 4230 Administered Subcutaneously in Patients With Advanced Solid Tumors
|
|
26 Feb 2019 |
U.S. FDA Grants Breakthrough Therapy Designation (“BTD”) to Amicus’ AT-GAA in Late Onset Pompe Disease
|
|
24 Feb 2019 |
PharmaEssentia and AOP Orphan Receive EU Approval of Besremi™ (Ropeginterferon Alfa-2b) for Treatment of Polycythemia Vera (PV) in EU
|
|
24 Feb 2019 |
Bexion Pharmaceuticals Announces the Opening of Phase I Part 3 First-in-Human Trial Using BXQ-350 for the Treatment of Cancer
|
|
24 Feb 2019 |
Phoenix Tissue Repair Doses First Patient in Phase 1/2 Clinical Trial of PTR-01 (BBP-589) for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
|
|
21 Feb 2019 |
Foresee Pharmaceuticals Announces Successful Topline Results from Phase 3 Registration Study of LMIS 25 mg in Prostate Cancer
|
|
21 Feb 2019 |
AzurRx BioPharma Announces First Patients Dosed in Phase II OPTION Clinical Trial
|
|
20 Feb 2019 |
Novo Nordisk receives US FDA approval of ESPEROCT® (turoctocog alfa pegol, N8-GP)
|
|
20 Feb 2019 |
Pfenex Announces FDA Acceptance of NDA for PF708
|
